Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01172496 · ClinicalTrials.gov registry record · Phase 1

A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets and Oral Solution in Healthy Volunteers

A Phase 1 study, sponsored by United Therapeutics.

Completed
Registry status
Phase 1
Development phase
24
Enrollment target

NCT01172496: Completed Phase 1 study, sponsored by United Therapeutics.

NCT01172496 is a Phase 1 study that has completed, run by United Therapeutics. The registered enrollment target is 24 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01172496, a Phase 1 study, has completed, sponsored by United Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
24 participants
Enrollment target

Study Summary

This single center, open label, randomized, two-period, two-sequence cross-over study is designed to evaluate the relative bioavailability of a treprostinil diethanolamine 1 mg tablet in reference to treprostinil diethanolamine 1 mg oral solution (administered as four 0.25 mg doses every 2 hours for a 1 mg total dose) in twenty-four healthy volunteers. Other secondary outcomes of interest include assessment of pharmacokinetic parameters of treprostinil diethanolamine 1 mg tablets and a treprostinil diethanolamine 1 mg oral solution administered as four doses (0.25 mg every 2 hours for a 1 mg total dose) and evaluation of the safety and tolerability of each treatment regimen.

Primary Outcome

Pharmacokinetic blood sampling will occur twice for each subject. Pharmacokinetic parameters will be derived from treprostinil concentration-time data

Interventions

  • DRUG treprostinil diethanolamine

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2010-08
Phase Phase 1
United Therapeutics

63 total trials

What the finished NCT01172496 record still lists

NCT01172496 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower).

The record links to 0 conditions, and to 1 intervention - of which treprostinil diethanolamine is the first listed.

NCT01172496 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01172496 about?

NCT01172496 is a clinical study titled "A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets and Oral Solution in Healthy Volunteers". This single center, open label, randomized, two-period, two-sequence cross-over study is designed to evaluate the relative bioavailability of a treprostinil diethanolamine 1 mg tablet in reference to treprostinil diethanolamine 1 mg oral solution (administered as four 0.25 mg doses every 2 hours for...

What is the current status of trial NCT01172496?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2010-08.

What interventions are being tested in trial NCT01172496?

The interventions under investigation include: treprostinil diethanolamine (DRUG).

Who is sponsoring clinical trial NCT01172496?

This trial is sponsored by United Therapeutics, which has 63 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01172496's enrollment target sits among peer trials

24 1520th of 2000 higher than 405 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01172496, the US trial registry maintained by the National Library of Medicine. NCT01172496 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.